Edward Shin, MD
Interventional Pain Management · Plano, TXNPI 1427084433
Payments from drug & device makers
Across 119 payments — averaging $18.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$459
- Collegium Pharmaceutical, Inc.$246
- Biohaven Pharmaceutical Holding Company Ltd.$186
- Si-bone, Inc.$141
- Lundbeck LLC$136
- Lilly USA, LLC$126
- plus $962 from 19 others
What the payments were for
- Food & beverage$2,256100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 24 | $459 |
| Collegium Pharmaceutical, Inc. | 21 | $246 |
| Biohaven Pharmaceutical Holding Company Ltd. | 11 | $186 |
| Si-bone, Inc. | 2 | $141 |
| Lundbeck LLC | 7 | $136 |
| Lilly USA, LLC | 8 | $126 |
| Boston Scientific | 6 | $105 |
| Arbor Pharmaceuticals, Inc. | 3 | $88 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $87 |
| Forte Bio-pharma LLC | 1 | $83 |
| Abbott | 2 | $73 |
| Medtronic(2 entities) | 3 | $67 |
| Azurity Pharmaceuticals, Inc. | 4 | $64 |
| Pfizer | 3 | $56 |
| Scilex Pharmaceuticals Inc. | 4 | $56 |
| Biohaven Pharmaceuticals, Inc. | 2 | $49 |
| Novartis | 3 | $48 |
| International Rehabilitative Sciences, Inc | 1 | $43 |
| Valinor Pharma, LLC | 2 | $35 |
| Amgen | 2 | $25 |
| Redhill Biopharma Inc. | 1 | $21 |
| MDD US Operations, LLC | 1 | $18 |
| Idorsia Pharmaceuticals US Inc | 1 | $16 |
| Hikma Pharmaceuticals USA | 1 | $14 |
| Assertio Therapeutics, Inc. | 1 | $14 |
How this compares
Too few interventional pain management providers in Texasto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 679 | $18,384 |
| OxycontinOxycodone Hcl | 23 | $13,053 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 175 | $4,775 |
| Lidocaine | 29 | $3,720 |
| Gabapentin | 270 | $2,920 |
| Naloxone Hcl | 36 | $2,319 |
| Oxycodone Hcl | 124 | $2,163 |
| Tramadol Hcl | 219 | $1,861 |
| Morphine Sulfate ErMorphine Sulfate | 47 | $1,780 |
| Acetaminophen-CodeineAcetaminophen With Codeine | 45 | $745 |
| Pregabalin | 73 | $589 |
| Hydromorphone Hcl | 38 | $446 |
| Cyclobenzaprine Hcl | 30 | $319 |
| Celecoxib | 15 | $209 |
| Methocarbamol | 24 | $196 |
Paid to pharmacies, not to this prescriber.
Other interventional pain management in Plano
- Neil AtlinDallas$3K
- Arnulfo CarrascoSan Antonio$0
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.